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ABSTRACT
RNA-interference (RNAi) is a potent tool for specific
gene silencing. In this study, we developed an
adenovirus for conditional replication in p53-
dysfunctional tumor cells that uses p53-selective
expression of a microRNA-network directed against
essential adenoviral genes. Compared to a control
virus that expressed a scrambled microRNA-
network, antiviral RNAi selectively attenuated viral
replication in cells with transcriptionally active p53,
but not in p53-dysfunctional tumor cells where both
viruses replicated equivalently. Since these results
were confirmed by an in vivo comparison of both
viruses after infection of p53-knockout and normal
mice, we could demonstrate that attenuated replica-
tion was indeed a result of p53-selective exhibition
of antiviral RNAi. Addressing the therapeutic
applicability, we could show that the application
of RNAi-controlled virus efficiently lysed p53-
dysfunctional tumors in vitro and in vivo but resulted
in drastically reduced load of virus-DNA in the liver of
treated mice. We have generated a broadly applica-
ble adenovirus for selective destruction of p53-
dysfunctional tumors and thereby demonstrate
that virus-encoded RNAi-networks represent an
efficient and versatile tool to modify viral functions.
RNAi-networks can be applied to all trans-
criptionally regulated DNA-viruses to remodulate
viral tropism and thus provide means to generate
specifically replicating vectors for clinical
applications.
INTRODUCTION
RNA-interference (RNAi) has been established as versa-
tile tool for targeted gene repression during recent years.
The potent and speciﬁc gene silencing eﬀect of RNAi pro-
mises enormous potential for the treatment of disorders
with deﬁned genetic etiology. RNAi has been successfully
applied to revert oncogenesis by downregulation of
K-ras
V12 or Bcr-Abl (1,2), or to prevent acute liver failure
by silencing Fas or Caspase-8 (3,4).
Exogenous delivery of RNAi, directed against viral
RNA, has been shown to reduce viral titers of HIV, polio-
virus, HCV and Adenovirus (5–8), indicating that RNAi
can provide eukaryotic cells with a speciﬁc antiviral
defence mechanism. An endogenous human microRNA
(miR-32) has been discovered that negatively interferes
with replication of primate foamy virus-1 (9) and it
has been suggested that cell type-speciﬁc patterns of
microRNAs contribute to the cellular tropism of certain
viruses (10). Recently, virus tropism has been successfully
remodulated by incorporating target sites for natural,
tissue-speciﬁc microRNAs into the 30-UTR of essential
virus genes (11–13). These studies indicate the potential
of RNAi-based mechanisms for the generation of
tropism-modiﬁed viruses.
Some DNA-viruses encode for self-reactive miRNAs,
that have been considered to play a pivotal role in the
correct timing of the lytic life cycle (14,15). The use of
microRNAs as a regulative tool to manipulate the viral
tropism seems to be ideal since miRNAs are non-antigenic
structures of short length in contrast to the high immuno-
genicity of viral proteins and with respect to the size
constraints in viral genomes. However, it has not yet
been investigated whether tissue-speciﬁc expression of
engineered, antiviral miRNAs can be used to manipulate
the viral tropism.
Tissue-speciﬁc control of replication is an important
tool to remodulate the tropism of adenoviruses for the
treatment of solid tumors and several concepts have suc-
cessfully addressed prominent pan-cancer associated
molecular targets such as telomerase, Rb or p53 (16).
In the majority of human cancers p53-dependent tran-
scriptional activity is either suppressed or missing due to
*To whom correspondence should be addressed. Tel: +49 511 532 9401; Fax: +49 511 532 2021; Email: kuehnel.florian@mh-hannover.de
Correspondence may also be addressed to Stefan Kubicka. Tel: +49 511 532 6766; Fax: +49 511 532 2021; Email: kubicka.stefan@mh-hannover.de
 2009 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.genetic loss or inactivating mutations, but also due to
epigenetic inhibition. Loss of transcriptional functions
of p53 (further referred to as p53-dysfunction) is a funda-
mental step towards malignant cell transformation and
represents an excellent broad range target for molecular
interventions. In this study we have redesigned an adeno-
virus for conditional replication in p53-dysfunctional
tumors by p53-selective expression of an antiviral RNAi-
network. We could demonstrate that p53-dependent
expression of such a network is able to selectively control
viral replication due to eﬃcient knockdown of essential
viral genes and allows for eﬃcient replication and lysis
in p53-dysfunctional tumors in vitro and in vivo.
MATERIALS AND METHODS
Cell lines and culturing
Hep3B, H1299, HepG2, Huh7, A549, 293, HCT-116 and
primary human IMR90-ﬁbroblasts were obtained from
ATCC. HCT116 and HCT116-p53(–/–) were kindly pro-
vided by B. Vogelstein. All cells were maintained in
DMEM+Glutamax (Life Technologies Inc.) supplemen-
ted with 10% heat-inactivated FBS (Life Technologies
Inc.), 100units/ml penicillin and 100mg/ml Streptomycin
(Seromed) at 378Ci n5 %C O 2. For culturing of
HCT116-p53(–/–) the medium was additionally supple-
mented with 0.4mg/ml G 418-Sulfate (Calbiochem) and
0.1mg/ml Hygromycin (Boehringer Mannheim).
RNAi target sequences
The following target sequences were chosen for con-
struction of antiviral RNAi-networks. Fireﬂy luciferase:
GAUUUCGAGUCGUCUUAAUGU [shRfLuc-774, as
described previously (17)]; E1A: GGAGGCGGTTTCG
CAGATTTT (shRE1A-736), GAAGGGATTGACTTA
CTCACTTTT (shRE1A-785); E4: GACAGGAAACCG
TGTGGAATA (shRE4-33056), CCATGTTTAATCAG
AGGTTTATA (shRE4-33623); E1B: GGAAGCATTGT
GAGCTCATAT (shRE1B-3630); pTp: CGGAGTACCT
ACACAACAATT (shRpTp-9651); Adpol: GCGAATAC
GTGCAGCTAAACAT (shRAdPol-6361). Further
sequence details of used oligonucleotides can be provided
upon request.
Genetic construction
Expression vectors for miR30-shRNA-motifs were con-
structed using pBluescript provided with synthetic poly-
linker, a SV40-polyadenylation signal derived from
AdApt (Introgene), and a promoter, such as the wildtype
CMV-promoter (from pBK-CMV, Stratagene), U6-
promoter (pSuperRetro, Addgene), or the p53-responsive
promotor prMinRGC from prMinRGC-Luc (18). For
the generation of miR30-shRNA-motifs, two partially
overlapping oligonucleotides were annealed and over-
hangs were then ﬁlled-in using Herculase (Stratagene).
Restriction sites were introduced by a second PCR using
TTCTCGAGAAGGTATATTGCTGTTGACAGTGAG
CG and AAAACTAGTGAATTCCGAGGCAGTAGG
CA as primers. The obtained fragments were inserted
into the aforementioned expression vectors. All miRNA-
sequences for miR30-shRNAs were designed using a pub-
licly available algorithm (http://katahdin.cshl.org:9331/
siRNA/RNAi.cgi?type=shRNA). For experimental eval-
uation of candidate RNAi sequences, the psiCHECK-2
reporter system (Promega) was used. DNA fragments cor-
responding to viral target messengers [spanning following
regions: 541–926 (E1A), 3608–4070 (E1B), 33704–32881
(E4), 10214–9365 (pTp), 6809–6106 (Adpol)] were gener-
ated by PCR using adenoviral DNA as template and
cloned into the 30-UTR of the Renilla reporter gene.
Shuttle plasmids for the generation of recombinant
adenovirus were constructed on the basis of the
plasmid pHM3. pHM3–E1 was constructed by insertion
of N22–E1A under control of the wildtype E1A-
promotor. The vector also contained the E1B region
up to the translational stop of E1B–55k (pos. 3509) fol-
lowed by the adenoviral sequence according to pos. from
3614–3661 to obtain a further target site within the
30UTR of E1B–55k. To further enhance RNAi eﬃcacy,
pHM3–E1–30-UTR was generated by additional insertion
of a fragment harboring the target sequences of shRE1A-
785, shRE1A-736 and shRE1B-3630 into the Hpa I site of
the E1A–30-UTR in pHM3-E1. p53-dependent expression
cassettes for multiple miR30-shRNAs were inserted
downstream of the E1 regions of pHM3–E1 and
pHM3–E1–30-UTR to generate shuttle vectors for sub-
sequent transfer into pAdHM4.
Full-length E1A was PCR-ampliﬁed from adenoviral
DNA using the primers GGGACTAGTAAAATGAGA
CATATTATCTGCCACGG and AAGCGGCCGCTTA
TGGCCTGGGGCGTTTACA and placed in an expres-
sion vector under control of an EF1a-promoter (obtained
from pLVTHM, kindly provided by D. Trono).
Further details concerning cloning procedures or used
oligonucleotides can be provided upon request.
Recombinant adenovirus generation and preparation
Recombinant adenoviruses were constructed according
to a previously described method (19). The viral vectors
Ad-iREP-C1, Ad-iREP-1, Ad-iREP-C2 and Ad-iREP-2
were generated by ligating PI-Sce I/I-Ceu I fragments of
shuttle pHM3-vectors described above into pAdHM4.
For the production of infectious particles the resulting
plasmids were Pac I-digested and transfected into 293
cells until a cytopathic eﬀect became visible. Infectious
particles were further ampliﬁed in 293 cells and then pur-
iﬁed using Adpack20-Kit (Vivascience). Infectious titers
were determined using the Rapid-Titer-Kit (Takara/
Clontech).
Luciferase assay
Using the calcium phosphate precipitation method or
LipofectAMINE
TM (Life Technologies), cells were
cotransfected with 1mg of pCMV-fLuc as reporter, 1mg
shRNA expression plasmids and 0.5mg SV40-LacZ for
normalization. Total DNA-amount was adjusted to 5mg
per 60mm. Cellular extracts were prepared 24–48h post
transfection and analyzed for luciferase activity in a
Berthold Lumat LB9501 and normalized by b-galacto-
sidase activity measurements.
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TM-2
derived vectors were cotransfected as reporter and the
Dual-Luciferase Reporter Assay System (Promega) was
applied.
Infection of IMR-90-fibroblasts
To allow eﬃcient infection of IMR-90-ﬁbroblasts, adeno-
viral vectors were coated with the bifunctional adapter
protein CARex-Tat as described previously (20). For this
purpose, viruses were mixed with puriﬁed recombinant
CARex-Tat protein (100ng/10
4 ifu) and incubated for
15min. Total 5 10
5 IMR-90-ﬁbroblasts were then
infected with pretreated viral particles at MOI 0.1.
Using the QIAmp-DNA-Mini Kit (Qiagen) total DNA
was isolated and subjected to qPCR to determine the
viral DNA-content.
Viral DNA-quantification
Quantitative PCR (qPCR
TM Mastermix Plus, Eurogentec)
was performed with 100ng of DNA using adenoviral
hexon-speciﬁc primer probes as described before (21).
As internal controls, the Ubiquitin-C-Control-Kit
(Eurogentec) was used for human DNA, and the 18S-
Genomic-Control-Kit (Eurogentec) was applied for
murine DNA.
Reverse transcription qPCR
Total 1.5 10
6 A549 and Huh7 cells were seeded in
60-mm-dishes and infected (MOI 0.05) with adenovirus
as indicated in the ﬁgure legends. Total RNA was isolated
using peqGOLD-RNAPure
TM (peQLab), digested with
DNase, and further puriﬁed using the RNeasy-Mini-Kit
(Qiagen). One hundred nanograms of RNA was subjected
to reverse transcription using random hexamer primer
and TaqMan
TM Reverse Transcription Reagents
(Applied Biosystems). cDNA was then used for quantiﬁ-
cation using SYBR-Green PCR Master Mix (Applied
Biosystems) and 30 cycles with 15s at 958C and 60s at
608C after an initial step for 10min at 958C. The ﬂuores-
cence signal was acquired at 608C. Amplicon signals were
normalized by GAPDH as internal control. Primer
sequences were GCCGGAGCAGAGAGCCTT (E1A-
fw); CGTCGTCACTGGGTGGAAAG (E1A-rev); GGC
CCCAATTTTAGCGGTAC (E1B-fw): GTCCAGGCTT
CCACACAGGTA (E1B-rev); AACTGGTCCGTTATG
GCCAA (pTp-fw); TGCACCTGCGTGAGGGTAG
(pTp-rev); TTTGTGGACCACACCAGCTC (Fiber-fw);
CAAGTATTTGACTGCCACATTTTGT (Fiber-rev);
TGGGCTACACTGAGCACCAG (GAPDH-fw); GGG
TGTCGCTGTTGAAGTCA (GAPDH-rev).
Detection of mature microRNAs/shRNAs
Mature microRNAs/shRNAs were detected and quanti-
ﬁed according to the miR-Q PCR method as described
previously (22). For this purpose 100ng of isolated total
RNA of infected cells were used for reverse transcription
of mature miRNA with speciﬁc reverse primer: TTTTGT
CAGGCACCGTATTCACCGTGAGTGGTACGGAG
GCG (QRT736) and TTTTGTCAGGCACGTTTCA
CCGTGAGTGGTACGACAGGA (QRT33056).
TaqMan
TM Reverse Transcription Reagents (Applied
Biosystems) were applied according to the manufacturer’s
protocol. Generated miR-cDNA was then applied for
quantiﬁcation using SYBR-Green PCR Master Mix
(Applied Biosystems). The reaction was performed using
100nM QRev736: CCCCGTCAGATGTCCGAGTAGA
GGGGGAACGGCGACAAAATCTGCGAAACCGC or
QRev33056: CCCCGTCAGATGTCCGAGTAGAG
GGGGAACGGCGACTATTCCACACGGTTTCC and
300nM of reverse and forward primers: TGTCAGGCA
ACCGTATTCACC (Q-fw) and CGTCAGATGTCCGA
GTAGAGG (Q-rev). The ampliﬁcation was carried out
by a ﬁrst step at 958C for 10min, followed by 30 cycles
with 15s at 958C and 60s at 628C. The ﬂuorescence signal
was acquired at 628C. Ampliﬁcation of GAPDH was used
as internal control.
Western blot analysis
For western blot analysis cell extracts were prepared by
treating the cell-layer with a lysis buﬀer containing 25mM
Tris-phosphate, 2mM EDTA, 2mM DTT, 10% glycerol
and 1% Triton X-100. Ten micrograms of protein were
separated by SDS–PAGE and transferred onto a PVDF-
membrane (Immobilon, Millipore). E1A-proteins were
detected using a polyclonal rabbit anti-E1A-antibody
(Santa Cruz) and visualized with Western-Lightning
TM
chemiluminescent-reagent Plus (Perkin-Elmer).
Cytolysis assays
Target cells were seeded in 24-well plates at a density of
4 10
4cells/well and allowed to adhere overnight. Cells
were then infected with adenoviruses (MOI of 5, 0.5,
0.05 and 0.005) and incubated for 8–10 days. Crystal-
violet staining was then used to visualize the destruction
of the cell layer. After a gentle rinse with PBS to remove
dead cells, 10% formalin in PBS was added for ﬁxation
(30min). The ﬁxation solution was replaced and cells were
then stained for 30min using an aqueous solution of 0.1%
crystal-violet in 10% ethanol. Finally, plates were rinsed
with water and air dried.
Animal experiments
Six-week-old, homozygous p53-knockout mice (inbred
from strain B6.129S2-Trp53
tm1Tyi/J, Jackson Laboratory,
Maine, USA) were provided by the Central Animal
Facility at the Helmholtz Centre of Infection Research
(HZI, Braunschweig, Germany). Six weeks old C57BL/6
and NMRI nu/nu mice were obtained from the Animal
Research Institute of the Hannover Medical School. All
experiments were performed according to the German
legal requirements (TSchG). Tumor xenografts were
established by subcutaneous injection of 1 10
7 Hep3B
or H1299 cells into the left ﬂank of mice. Tumor nodules
were grown to a size of approximately 250mm
3 before
initial treatment. Infection of tumors was performed by
intratumoral injection of 1 10
9 ifu in 150ml and was
repeated every ﬁve days. Tumor volume was calculated
as follows: V(tumor)=(length (width
2)/2. For each
group six animals were assessed.
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cells were infected at MOI 25 to achieve almost complete
infection. Twenty-four hours later, infected cells were
collected and 5 10
5cells were injected intravenously.
DNA from liver tissue was puriﬁed using the QIAmp-
DNA-Mini Kit (Qiagen) and viral DNA was quantiﬁed
by qPCR as described above.
Statistics
For the comparison of two groups, the Student’s t-test was
used to determine statistical signiﬁcance. P-values <0.05
were considered as statistically signiﬁcant.
RESULTS
RNA-polymerase II (pol II)-dependent expression of
shRNA or microRNA has already been successfully estab-
lished, suggesting that such RNAi mediators can be
expressed by virtually any promoter and that RNAi can
therefore be brought about in a tissue-speciﬁc manner
(23,24). To investigate in a therapeutically relevant setting
whether cell-type speciﬁc expression of virus-encoded
antiviral shRNA restricts virus propagation to deﬁned
tissues, we aimed to generate a conditionally replicating,
RNAi-controlled adenovirus for targeted therapy of
p53-dysfunctional tumors. To redirect adenoviral replica-
tion to p53-dysfunctional tumor cells, our concept
(Figure 1A) envisioned the expression of a multiple hair-
pin transcript (referred to as antiviral RNAi-network) that
eﬃciently silences a set of essential viral genes under tran-
scriptional control of a p53-responsive promoter. This
strategy allows selective onset of antiviral RNAi and
subsequent inhibition of viral replication in response to
activated p53 in normal cells. In contrast, the antiviral
RNAi-network is not expressed in p53-dysfunctional
tumor cells thus enabling normal adenoviral replication.
p53-dependent gene silencing by a multiple shRNA-
transcript consisting of concatenated, minimalized
miR30-derived hairpins
The genetic information for shRNAs can be encoded by
DNA of relatively short length. The concatenation of dif-
ferent shRNAs to construct an ‘RNAi-network’ should
further allow synchronous silencing of diﬀerent genes
involved in viral replication. As single modules for
such an RNAi-network, we considered a minimalized
miR30-derived hairpin (termed miR30-shR, Figure 1B)
according to designed hairpins described before (24).
To allow for p53-selective expression of shRNA we
chose the artiﬁcial, p53-responsive promoter prMinRGC
that we have described previously (18). As shown in
Figure 1C, this promoter is highly active in p53-normal
cells but silent in p53-dysfunctional cells. The
prMinRGC-promoter therefore displays an outstanding
signal/noise ratio with regard to the p53-status of the
target cell.To investigate whether shRNA can be expressed
in a p53-selective manner, the experiment was carried
out in p53-positive HepG2 and p53-mutant Huh7
cells (Figure 1D). Gene silencing eﬃcacy was then deter-
mined after shRNA-expression under control of the pol
III-dependent U6-promoter and pol II-dependent CMV-
and prMinRGC-promoters. We could observe eﬃcient
RNAi in HepG2 cells when shRNAs were expressed
under control of the prMinRGC-promoter, whereas
RNAi was absent under p53-dysfunctional conditions.
Following CMV-promoter dependent expression of
shRNA the observed extent of RNAi was almost equiva-
lent in both cell lines. Though pol II-dependent RNAi
did not reach the extent of pol III-dependent RNAi,
prMinRGC-promoter-dependent expression of shRNA
led to a similar extent of RNAi in response to p53 com-
pared to the strong CMV-promoter. This promoter has
already been successfully used for eﬃcient exhibition of
RNAi (23). The comparison of RNAi caused by
prMinRGC-promoter-dependent expression of shRNA in
cells with diﬀerent p53-status indicates that RNAi was
indeed p53-dependent. As these results were conﬁrmed in
other p53-active or p53-inactive cells (data not shown),
eﬃcient RNAi can be exhibited in a p53-selective manner.
Next, we were interested how gene silencing eﬃcacy is
inﬂuenced when miR30-shRs are concatenated to generate
complex RNAi-networks (concatenation is illustrated in
Figure 1B). For this purpose we tested several arrange-
ments that either varied in length of the network or
the position of a single miR30-shRfLuc-motif within the
network (Figure 2A). Since expression of all arrangements
led to an almost equivalent repression of the cotransfected
luciferase-reporter we could show that neither the length
of the RNAi-network nor the position of an active hairpin
signiﬁcantly inﬂuence gene silencing eﬃcacy. Together,
these data suggest that p53-dependent expression of
multiple hairpin-transcripts as RNAi-networks can be
applied to achieve eﬀective and synchronous gene silen-
cing and demonstrate the versatility of the RNAi-network
concept.
Antiviral RNAi-network silences essential viral genes
following viral infection
We considered the mRNAs of the adenoviral E1A, E1B,
E4, polymerase (AdPol) and terminal protein (pTp) as
preferable targets for an antiviral RNAi-network. E1A
and E4 proteins are most essential for replication and
E1B-55k is decisively involved in the shutdown of the
cellular p53-response. Terminal protein is bound to the
viral DNA–termini and attracts AdPol for the initiation
of replication. First, miR30–shR-derivatives of several
potential hairpin-motifs per target were screened for
their gene silencing eﬃcacy. Complete test results are
summarized in Figure 2B–D). To point out, we found
two eﬃcient hairpins against E1A that were also able
to successfully silence full-length E1A as conﬁrmed by
western blot analysis (Figure 2B). Interestingly, we could
observe that a tandem combination of the same miR30–
shR-motifs against E1A did not increase knockdown eﬃ-
cacy whereas the combination of diﬀerent motives resulted
in additional gene silencing (Figure 2C).
Most eﬀective hairpins were then concatenated
for an antiviral RNAi-network that was subsequently
introduced into an adenoviral backbone under the
control of the prMinRGC-promoter (Ad-iREP-1 and
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for RNAi mechanisms, we positioned additional RNAi
target-sites in the 30-UTRs of E1B (both viruses) and
E1A (only Ad-iREP-2). In all vectors we used an N-term-
inally deleted E1A that reduces negative interference
between E1A and p53/p300 and is known to allow wild-
type-like viral replication (25). We additionally generated
genetically identical control viruses (Ad-iREP-C1 for
Ad-iREP-1, and Ad-iREP-C2 for Ad-iREP-2, respectively,
Figure 3A) for expression of a nonfunctional shRNA-
network containing scrambled hairpins, instead of the
antiviral RNAi-network present in Ad-iREP-1/-2. Since
we have characterized the p53-status of the used cell
lines with regard to the on/oﬀ-response of the
prMinRGC-promoter (see Figure 1C), the comparison
of Ad-iREP-1/-2 and their corresponding control viruses
can be directly used to determine the inﬂuence of the anti-
viral RNAi-network.
First, we analyzed E1A protein levels after transfection
of the adenoviral shuttle plasmids into cells with diﬀerent
p53-status. As shown in the upper panel of Figure 3B,
transfection of both Ad-iREP-1 and Ad-iREP-2 shuttle
plasmids, but not the control vectors, led to down
regulation of E1A under p53-positive conditions. In con-
trast, no diﬀerence in E1A-levels was observed in p53-
dysfunctional cells suggesting that eﬀective repression of
E1A could be dependent of p53-selective activation of
RNAi. Important to note that E1A-silencing after trans-
fection of Ad-iREP-2 was more eﬀective than Ad-iREP-1
suggesting that the additional target-site within the
E1A-30-UTR conferred an improved accessibility for
RNAi. It has been shown that transient transfection of
cells is associated with signiﬁcant cell stress followed by
a strong accumulation of p53 (26). It has to be considered
that viral infections, in particular after low-dose applica-
tion, may induce p53 to a lower extent compared to the
transient transfection situation which could lead to an
overestimation of transfection results as described above.
Consequently, a less potent p53-response upon viral infec-
tion could compromise eﬀective induction of antiviral
RNAi. We therefore compared E1A-expression after cell
infection with the corresponding viruses. Consistent
with the transfection results, E1A-levels were signiﬁcantly
decreased in p53-positive cells after infection with Ad-
iREP-2 (Figure 3B, lower panel). E1A was not silenced
after infection with the control virus Ad-iREP-C2.
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Figure 1. Concept of p53-dependent, RNAi-mediated modiﬁcation of the adenoviral tropism. (A) Scheme of tumor selectively replicating adenovirus
that expresses a self-inhibitory, antiviral RNAi-network in response to p53. (B) Used miR30-shRNA-motifs and concatenation to generate RNAi-
networks (miR30-shRfLuc as example). (C) Activation of the p53-selective promoter prMinRGC in cell lines with diﬀerent p53-status. Cells were
cotransfected with prMinRGC-fLuc and CMV-LacZ. Luciferase activity was determined 48h post transfection (mean SD). The prMinRGC-
promoter is highly activated in p53-positive cell lines whereas activation is absent in p53-negative or mutated cells. (D) HepG2 and Huh7 cells
were cotransfected with CMV-fLuc, SV40-LacZ and shRNA-expression plasmids under control of a U6-, CMV- or prMinRGC-promoter (shRfLuc
relative to the corresponding shRScr-control, mean SD). The results show that RNAi can be expressed in a p53-selective manner.
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Huh7 cells with both viruses conﬁrmed p53-selectivity of
the E1A repression observed in the p53-positive cell lines.
Interestingly, E1A-silencing could not be observed after
infection with Ad-iREP-1. In the particular context of
viral infection, Ad-iREP-1-dependent RNAi insuﬃciently
suppressed E1A thereby conﬁrming the beneﬁcial inﬂu-
ence of the manipulations performed in the 30–UTR of
E1A. This ﬁnding also suggests that a low E1A threshold
is suﬃcient to allow the onset of replication. This obser-
vation also underlines the importance of stringent regula-
tive mechanisms for eﬃcient suppression of E1A to allow
targeted regulation of viral replication.
Next, we directly determined the expression of the anti-
viral RNAi-network by detection of mature miRNA using
the PCR-based miR-Q method as described previously
(22). Two hairpins against E1A and E4 were selected
to exemplify successful RNAi-network processing. We
could show a strong and equivalent increase of both inves-
tigated hairpins after infection of p53-positive cells with
Ad-iREP-1 and Ad-iREP-2 (Figure 3C). Since we could
not detect signiﬁcant amounts of hairpins in p53-mutant
Huh7 cells at early stages, our data clearly demonstrate
that the RNAi-network was expressed in a p53-selective
manner. In Huh7 cells only a small background could be
detected at 48h, a time-point that includes a full replica-
tion cycle. Interestingly, Ad-iREP-1 expressed comparable
amounts of the RNAi-network as Ad-iREP-2 at early
stages though this virus failed to repress E1A eﬃciently.
Again, this observation conﬁrms the relevance of the E1A-
30UTR manipulations to achieve better accessibility of
the target messenger. We then monitored expression of
several targeted genes (E1A, E1B and pTp) following
infection of p53-positive A549 cells to investigate the
activity of other RNAi-network components. As shown
in Figure 3D (upper panel), the expression of target
genes was eﬀectively reduced. In contrast, this was not
the case following infection of p53-mutant cells
(Figure 3D, lower panel). However, it has to be considered
in these experiments that levels of the corresponding
mRNAs are inﬂuenced by the number of viral genomes
if replication is indeed allowed or compromised. We there-
fore determined the expression of the viral ﬁber-mRNA
as a non-target of the antiviral RNAi-network. We
could measure a signiﬁcant reduction of ﬁber suggesting
that replication of viral DNA was actually alleviated. But,
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Figure 2. Optimization of an antiviral RNAi-network targeting essential adenoviral genes. (A) p53-dependent expression plasmids for complex
RNAi-networks with variable hairpin numbers and variable position of a single, embedded miR30-shRfLuc-motif were cotransfected with CMV-
fLuc and SV40-LacZ in HepG2 cells and investigated as described above (mean SD). (B) The psiCHECK-2-derived plasmids containing target
sequences of adenoviral E1A-mRNA within the 30-UTR of the renilla luciferase were used to evaluate eﬀective miR30-shRNAs against E1A. HepG2
cells were cotransfected with miR30-shRNA-expression constructs under control of the prMinRGC-promoter. Forty-eight hours later, cells were
lysed and luciferase activity was determined. Application of miR30-shRE1A-785 and miR30-shRE1A-736 led to eﬀective RNAi (mean SD). RNAi
eﬃcacy was conﬁrmed when the full-length messenger E1A was addressed. For this purpose, an expression construct for the complete E1A-mRNA
was cotransfected with a miR30-shRE1A-736-construct and E1A-level was analyzed by western blot (inset). (C) A psiCHECK-2-plasmid containing
an E1A-target fragment was cotransfected in HepG2 cells with plasmids for expression miR30-shRE1A tandem-arrangements as indicated and
luciferase activity was determined (mean SD). In a multiple miR30-shRNA transcript, RNAi is more eﬃciently exhibited by diﬀerent motives
compared to motif-repeats. (D) RNAi-eﬃcacy by diverse miR30-shRNA-motifs against psiCHECK-2-derived reporters of E4, E1B, pTp and AdPol
was determined. The black and dark grey bars indicate the most eﬀective miR30-shRNA-motifs that were selected for the antiviral RNAi-network.
e84 Nucleic Acids Research,2009, Vol. 37,No. 12 PAGE6 OF12Figure 3. p53-selective expression of the antiviral RNAi-networks inhibits expression of adenoviral target genes in vitro.( A) Design of p53-selective,
RNAi-controlled viruses containing either an inhibitory RNAi-network (Ad-iREP-1 and Ad-iREP-2) or a noninhibitory RNAi-network (consisting of
scrambled hairpins, Ad-iREP-C1 and Ad-iREP-C2) under control of the prMinRGC-promoter. All viruses expressed an N-terminally deleted version
of E1A under control of the E1A-wt promoter (prE1A). Ad-iREP-C2 and Ad-iREP-2 were provided with additional target sites by insertion into in the
3’-UTR of E1A-mRNA. (B) Shuttle plasmids were cotransfected with the luciferase reporter pGL2-Prom as internal standard into cells with diﬀerent
p53-status. E1A-silencing was investigated after 24h posttransfection by western blot analyses. Transfection eﬃcacy was controlled by luciferase
measurements (upper panel). Similar analyses were performed 24h after cell infection with corresponding adenoviral particles at MOI 0.05 (lower
panel). (C) A549 and Huh7 cells were infected with Ad-iREP-1 and Ad-iREP-2 at MOI of 0.05. Total RNA was isolated and mature miRNAs of miR30-
shRE1A-736 (left) and miR30-shRE4-33056 (right) were quantiﬁed using the miR-Q-RT-PCR method (mean SD) 12, 24 and 48h later. The data
conﬁrm that the RNAi-network is eﬃciently expressed in p53-positive cells but not in p53-dysfunctional cells. (D) Adenoviral expression of diﬀerent
RNAi-targets (E1A, E1B and pTp) and ﬁber as nontarget was investigated in cells with diﬀerent p53-status following infection with Ad-iREP-1,
Ad-iREP-2 and corresponding controls (A549: upper panel; Huh7: lower panel). At time-points indicated mRNA levels were determined by RT-
qPCR (mean SD). The data show that p53-selective expression of the antiviral RNAi-network by Ad-iREP-2 successfully silenced viral target genes.
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E1A, E1B and pTp suggesting that the hairpins directed
against E1B and pTp actually exhibited RNAi. However,
it is impossible to exactly calculate the contribution of the
other network components since these genes are more or
less downstream functions of genome ampliﬁcation in the
course of replication and thus of E1A expression.
Ad-iREP-2 mediates efficient lysis of p53-dysfunctional
cells but is selectively attenuated in normal cells
Next, we investigated whether the achieved knockdown
of adenoviral genes was suﬃcient to inhibit the genera-
tion of infectious progeny. We therefore monitored time-
dependent progression of adenoviral titers with regard to
the cellular p53-status (Figure 4A). For comparative
purposes we also included the adenovirus wildtype and
ONYX-015, an adenovirus mutant that has been
initially described to replicate preferentially in p53-
dysfunctional cells and has already been tested in clinical
trials. In p53-positive, A549 cells eﬃcient attenuation of
viral replication could be observed only after infection
with Ad-iREP-2, when compared to the non-regulated
Ad-iREP-C2 as standard. In line with the lower eﬃcacy
of E1A-silencing described above, attenuation of
Ad-iREP-1 was modest. Since all RNAi-controlled viruses
replicated to a similar extent compared to their control
viruses in p53-dysfunctional Huh-7 and Hep3B cells we
conﬁrmed that the inhibition of viral replication was due
to antiviral RNAi-activity in response to active p53. These
results could be further conﬁrmed in other cell lines such as
p53-positive HepG2 and p53-deleted H1299 cells (data not
Figure 4. Ad-iREP-2 dependent replication and cell lysis are selectively inhibited in the presence of active p53. (A) Cells were infected at MOI 0.01,
harvested at indicated time-points and lysed by repeated freezing/thawing to determine viral titers. In A549, but not in Hep3B cells or Huh7 cells,
replication of Ad-iREP-2 is signiﬁcantly inhibited compared to the control Ad-iREP-C2 [mean SD, statistical analyses for A549 at 120h: Ad-iREP-
1 versus Ad-iREP-C1 (P=0.044); Ad-iREP-2 versus Ad-iREP-C2 (P=0.003); Ad-iREP-2 versus Ad-iREP-1 (P=0.01); Ad-iREP-2 versus ONYX-
015 (P=0.030); Ad-iREP-1 versus ONYX-015 (not signiﬁcant); Ad-iREP-C1 versus Ad-iREP-C2 (not signiﬁcant)]. (B) For cytolysis assays cells
were infected at diﬀerent MOIs as indicated. As demonstrated by crystalviolet stainings, Ad-iREP-2 shows improved lytic eﬃcacy and p53-selectivity
compared to ONYX-015. (C) Primary human IMR-90 ﬁbroblasts were infected at MOI 0.1. To mediate eﬃcient transduction viral particles were
treated with CARex-Tat as described in the methods section. At indicated time-points, total DNA was isolated and the viral DNA-content
was determined. The results indicate that DNA-replication of both Ad-iREP-1 and Ad-iREP-2 was signiﬁcantly attenuated in primary human
ﬁbroblasts [mean SD, statistical analyses for A549 at 72h: Ad-iREP-1 versus Ad-iREP-C1 (P=0.008); Ad-iREP-2 versus Ad-iREP-C2
(P=0.003); Ad-iREP-2 versus Ad-iREP-1 (P=0.041); Ad-iREP-2 versus ONYX-015 (P=0.012); Ad-iREP-1 versus ONYX-015 (P=0.017);
Ad-iREP-C1 versus Ad-iREP-C2 (not signiﬁcant)].
e84 Nucleic Acids Research,2009, Vol. 37,No. 12 PAGE8 OF12shown). p53-selectivity of Ad-iREP-2 was improved com-
pared to ONYX-015, since ONYX-015 replicated like Ad-
iREP-1 in A549 cells. In contrast, ONYX-015 showed
weakerreplicationthanRNAi-controlledvirusesinallp53-
-altered cell lines except Hep3B. However, Hep3B cells are
known to intrinsically support adenoviral replication by
expressionofHBx(27).Mostlikelyduetoextensivegenetic
manipulations and the used N-terminally deletion mutant
of E1A, all RNAi-viruses showed slightly reduced replica-
tion when compared to the wildtype adenovirus.
Eﬀective oncolysis is a central requirement for condi-
tionally replicating adenoviruses as extensive genetic
manipulations can also aﬀect lytic eﬃcacy. Comparing
both p53-selectivity and lytic eﬃcacy of RNAi-viruses,
ONYX-015 and Ad-wt in vitro, we found that only
Ad-iREP-2-mediated oncolysis was signiﬁcantly attenu-
ated in p53-positive cells, since Ad-iREP-1/-2 and the
non-regulated Ad-iREP-C1/-C2 lysed p53-dysfunctional
Huh7 and H1299 cell to the same extent (Figure 4B).
Furthermore, we could observe that Ad-iREP-2 oncolysis
was attenuated in p53-positive HCT-116 cells but not in
their isogenic counterpart HCT-116 p53–/–. Interestingly,
Ad-iREP–1-mediated lysis was comparable to Ad-iREP-
C1 showing that the observed diﬀerences in viral titers
were insuﬃcient to result in p53-selective cell lysis. With
exception of Hep3B, wherein only small diﬀerences
in oncolysis could be observed, and consistent with the
titration results described above, Ad-iREP-2 was able to
lyse p53-dysfunctional cells signiﬁcantly more eﬃcient
than ONYX-015. Though RNAi-viruses did not reach
the lytic eﬃcacy of the wildtype, our data demonstrate
that Ad–iREP–2 combined higher selectivity for p53 and
improved lytic eﬃcacy compared with ONYX-015.
Transformed cells provide a convenient microenviron-
ment for viral replication and may not reﬂect the spectrum
of a natural p53-response in primary cells. We therefore
investigated viral replication in primary adult human
ﬁbroblasts (Figure 4C). However, ﬁbroblasts are highly
resistant against adenoviral transduction. For eﬃcient
transduction at low MOI, viral particles were pretreated
with the bispeciﬁc CARex-Tat as described before (18).
This allows for eﬃcient cell entry and subsequent moni-
toring of replication for at least one cycle. Due to these
constraints, the more sensitive determination of viral
DNA ampliﬁcation as indicator of replication was
chosen. Our results demonstrate that DNA replication
of both RNAi-controlled viruses Ad-iREP-1 and Ad-
iREP-2 was signiﬁcantly inhibited compared to the con-
trol viruses thus demonstrating the p53-selective eﬀect of
antiviral RNAi in primary human cells. In these cells both
Ad-iREP-1 and Ad-iREP-2 showed improved selectivity
compared to ONYX-015.
RNAi-controlled adenoviral replication allows for efficient
oncolysis in mouse xenograft models and leads to reduced
intrahepatic load of viral DNA
In the course of a tumor treatment with conditionally
replicating adenoviruses, viral progeny is permanently
released by infected malignant tissue. Due to the dominant
hepatotropism of adenoviral particles in vivo, adenoviral
hepatitis poses a considerable threat to the liver.
Therefore, tight control of conditional replication is
decisive to reduce the liver burden. We addressed this
question by experiments in mice though we were aware
that adenovirus does not produce infectious progeny in
murine cells. However, murine cells almost normally
amplify the adenoviral genomes which allows for an esti-
mation of a possible liver threat. In a ﬁrst experiment, we
tested intrahepatic load of adenoviral DNA after systemic
injection of virus in p53-normal mice (Figure 5A),
and p53-knockout mice respectively (Figure 5B). We
could observe that viral DNA-levels after application of
replication-competent virus types increased in time.
This was a result of DNA-replication since application
of a replication-incompetent Ad-LacZ-virus did not lead
to increasing levels of intrahepatic adenoviral DNA.
Compared to the control Ad-iREP-C2, the amount of
Ad–iREP–2-DNA was substantially reduced in the liver
of normal mice but not of p53-knockout mice suggesting
that p53-dependent expression of the antiviral RNAi-net-
work inhibited viral replication in vivo. In contrast, Ad-
iREP-2 and the control-virus replicated to a similar extent
in p53-knockout mice demonstrating that inhibited repli-
cation in the livers of normal mice can be clearly attrib-
uted to the p53-dependent function of the RNAi-network.
In this experimental setup in normal mice, Ad-iREP-2
replication was only slightly lower than ONYX-015.
However, intravenous injections do not suﬃciently reﬂect
the constant release of adenoviral progeny that can be
expected during virotherapy of tumors. The pulsed entry
of high particle doses results in overinfection of peripheral
regions in the portal ﬁelds of the liver and it has been
shown that high multiplicities of infection can result in
diminished selectivity of conditionally replicating adeno-
viruses (28). We therefore investigated adenoviral liver
load in an improved murine model of viral oncolysis
that simulates a more constant release of viral progeny
into the blood ﬂow. To this end we injected preinfected
Hep3B cells into the tail vein of nude mice. Hep3B
cells provide a comparable production and release of the
investigated viruses (see Figure 4A and B). As shown in
Figure 5C, we observed a strong DNA-replication of the
control virus and to a slightly lesser extent of ONYX-015
in the livers of infected mice. In contrast, replication of
Ad-iREP-2 was almost undetectable, conﬁrming the tight
control of viral replication due to p53-transcriptionally
regulated RNAi-network expression in vivo.
To investigate the eﬃcacy of Ad-iREP-2-virotherapy
in vivo, subcutaneously grown H1299 and Hep3B tumors
were treated with repeated intratumoral adenovirus injec-
tions (Figure 6A and B). Subsequent monitoring of tumor
growth revealed that both Ad-iREP-2 and ONYX-015
comparably retarded the growth of Hep3B-tumors. In
contrast, Ad-iREP-2 lysed H1299-tumors more eﬀectively
compared to the rather ineﬀective ONYX-015. However,
intratumoral application of Ad-iREP-2 resulted in a
strong inhibition of tumor growth in this aggressively
growing tumor model. On the other hand, systemic
delivery of oncolytic adenoviruses following a similar
administration scheme did not result in a signiﬁcant
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tion (data not shown).
Together, our results indicate that Ad-iREP-2 regulates
its own replication in response to p53-dependent onset
of antiviral RNAi. Furthermore, Ad-iREP-2 is an eﬀec-
tive oncolytic adenovirus for the oncolytic therapy of
p53-altered tumors.
DISCUSSION
The special attractiveness of tumorselective viral replica-
tion is the idea that oncolytic viruses reproduce themselves
at the therapeutic locus functioning thereby like molecu-
lar surgery. Inactivation of the tumor suppressor p53
represents an excellent molecular target for the develop-
ment of broadly applicable anti-neoplastic agents such as
oncolytic viruses. In our study, we could demonstrate that
the engineered oncolytic adenovirus Ad-iREP-2 selectively
lyses cells with missing transcriptional activity of p53,
a dysfunction that encompasses most tumor-associated
p53 alterations including gene loss, inactivating mutations
and expression of proteins that negatively interfere
with p53-function and stability. Interdependence between
Ad-iREP-2-replication and p53-transcriptional deﬁciency
was achieved by p53-dependent onset of vector-encoded
antiviral RNAi that suppresses essential adenoviral genes
such as E1A, E1B, E4, pTp and AdPol. Since we could
prove eﬀective replication and potent lytic properties in
p53-dysfunctional cells and eﬀective inhibition of tumor
growth in vivo, Ad-iREP-2 represents an oncolytic vector
for the majority of human cancers. Regarding p53-
selectivity and lytic potency, Ad–iREP–2 was signiﬁcantly
improved compared to ONYX-015, an E1B-55k-deleted
adenovirus that has been initially proposed to selectively
replicate in p53-deﬁcient cells. Though ONYX-015
revealed favorable toxicity and therapeutic eﬃcacy in clin-
ical studies, at least in combination with chemotherapy, it
has been reported that ONYX-015 replication does not
correlate with the p53-status (29,30) but with other molec-
ular characteristics of the target cell (31,32). These ﬁndings
can explain the signiﬁcant attenuation of ONYX-015 in
many cancer cells and suggest that ONYX-015-replication
is only eﬀective in a limited subgroup of tumors that can
intrinsically compensate for the E1B-55k-deﬁciency.
Consistently, in our assays ONYX-015 replicated less eﬃ-
ciently than Ad-iREP-2 in most tumor cells except in
Hep3B that intrinsically support adenoviral replication
by expression of the HBV-derived X-protein (27).
Therefore deletion of crucial viral genes such as E1B-55k
can result in a severe loss of oncolytic potency. To ensure
potent replication in all cancer cells Ad-iREP-2 provides
expression of wildtype E1B-55k that exhibits several
essential functions such as support of viral mRNA-
export, host protein shut-oﬀ and enhancement of cyclin
E-expression (33,34).
On the other hand, E1B-55k is a potent inactivator of
p53-dependent transcriptional activity, either alone or in
concert with E4orf6. Additionally, p53-dependent tran-
scription appears to be generally inhibited by adenoviral
replication, even in the presence of mutated E1B-55k and
accumulated p53, suggesting that cellular p53-dependent
transcription and adenoviral replication are mutually
exclusive (35). Therefore, with regard to the presence of
wild-type E1B-55k, stringent regulative tools are needed
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Figure 5. Ad-iREP-2 administration in vivo leads to reduced intrahepa-
tic viral DNA-replication and viral DNA-load in the livers of treated
mice. p53-normal (A) or p53-knockout mice (B) were injected intrave-
nously with 1 10
7 infectious particles. At indicated time-points,
DNA was prepared from liver tissue and the content of viral DNA
was determined by qPCR. In normal mice, Ad-iREP-2 replication was
inhibited compared to the control Ad-iREP-C2 whereas both viruses
replicated comparably in p53 knockout mice thus proving the inhibi-
tory activity of the RNAi-network in vivo (mean SD;  P<0.05;
  P<0.01; ns=not signiﬁcant). (C) Viral replication in the liver was
investigated in a model that simulates a virotherapeutic setting. 5 10
5
Preinfected Hep3B cells/mouse () were injected with into the tail vein
and viral DNA load was investigated in liver tissue as described above.
The data suggest that Ad-iREP-2 replication is almost completely
inhibited and selectivity is signiﬁcantly improved compared to the
control Ad-iREP-C2 (mean SD;  P<0.05;   P<0.01).
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replication. E1A is expressed ﬁrst after adenoviral DNA
has entered the nucleus and is essential for cell cycle entry,
feed-forward activation of viral promoters and viral repli-
cation. We could demonstrate that the p53-dependent
expression of an antiviral RNAi-network is able to eﬃ-
ciently inhibit E1A-expression resulting in selective atten-
uation of viral replication in both primary human cells
and transformed human cells with active p53.
In another study, it has been demonstrated that the
adenovirus 01/PEME, targeting both p53-dysfunction
and E2F-activation in tumors, was attenuated in primary
human cells (25). However, the p53-dependent expression
of an E2F-antagonist, used by 01/PEME to achieve con-
ditional replication, was not suﬃcient to inhibit replica-
tion in A549 and HepG2 cells, despite transcriptionally
active p53. As Ad-iREP-2-replication was signiﬁcantly
inhibited in these cell lines, we could prove the regulative
stringency of the antiviral RNAi-network.
Finally, the p53-dependence of RNAi-controlled viral
replication was also conﬁrmed in vivo. Assessment of
viral DNA-load in the livers of intravenously infected
mice revealed a signiﬁcant inhibition of Ad-iREP-2
replication compared to the control virus Ad-iREP-C2
that express a scrambled network in response to p53.
This inhibition could not be observed after infection of
p53-knockout mice conﬁrming the p53-selective eﬀect of
the antiviral RNAi-network. However, both intravenous
and intratumoral injection of oncolytic viruses result in a
short term systemic viral burst constraining a reasonable
evaluation of the speciﬁcity of viral replication. In an
improved in vivo model that simulates constant, systemic
release of viral progeny during oncolytic therapy, we could
demonstrate an almost complete inhibition of Ad-iREP-
2-replication, conﬁrming the high speciﬁcity of RNAi-
controlled viral replication in vivo.
Natural microRNAs frequently occur as long clustered
transcripts that are expressed by RNA-polymerase II, and
polycistronic plasmid vectors for expression of RNAi-
network have already been established (36) suggesting
that multiple short-hairpin or microRNA-transcripts can
be used as convenient tool for diﬀerential gene regulation
(37). By application of a vector-encoded antiviral RNAi-
network to restrict adenoviral replication to tumor cells we
were able to demonstrate that RNAi is powerful enough to
interfere with viral replication and provides a mean to
manipulate the virus tropism. We achieved a decisive
improvement of the selective regulation by positioning
additional miRNA target sites within the 30-UTR of E1A
to render it more susceptible to RNAi. It can therefore be
assumed that the antiviral RNAi-network concept leaves
enough space for further optimization as merely this single
manipulation led to a visible advancement. RNAi-net-
works oﬀer an outstanding versatility regarding the
number of genes that can be synchronously targeted. As
they need only little space compared to conventional pro-
tein-basedgeneregulationsystems,theycanbeeasilyincor-
porated in viral vectors with limited capacity for the uptake
of heterologous DNA.
In conclusion we have shown that virus-encoded anti-
viral RNAi can be used for the self-control of viral vector
replication. The tumor selectivity of our virus was
achieved by an RNAi-network directed against essential
viral genes that is solely expressed in response to transcrip-
tionally active p53. RNAi-controlled viral replication
showed an improved speciﬁcity and antitumoral eﬃcacy
in vitro and in vivo compared to an isogenic control virus
that expresses a nonfunctional RNAi-network. As our
concept is principally applicable to other transcriptionally
regulated DNA viruses, the strategy of antiviral RNAi-
networks provides a general method for the generation
of a broad spectrum of selective viruses.
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Figure 6. Ad-iREP-2 virotherapy eﬃciently inhibits growth of p53-inactive tumors in vivo. For the investigation of oncolytic eﬃcacy in vivo,
subcutaneously grown Hep3B (A) or H1299 (B) tumors on nude mice were treated by repeated intratumoral injection of 1 10
9 pfu/injection.
Virus administrations are marked by arrows. Tumor growth was monitored until the trial was aborted due to the tumor burden of controls. Ad-
REP-2 application resulted in eﬃcient tumor growth inhibition in both xenograft models and was improved compared to ONYX-015 in H1299
[mean SD, statistical analyses for Hep3B tumor at Day 20: Ad-iREP-2 versus w/o virus (P=0.035); Ad-iREP-2 versus ONYX-015 (not signiﬁ-
cant); ONYX-015 versus w/o virus (P=0.047); for H1299 tumor at Day 20: Ad-iREP-2 versus w/o virus (P=0.004); Ad-iREP-2 versus ONYX-015
(P=0.005); ONYX-015 versus w/o virus (not signiﬁcant)].
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